Clinical trials: Surgery of Breast Cancer
Breast Neoplasm
SAVI SCOUT Clinical Evaluation Study
The purpose of this study is to evaluate the performance of the SAVI SCOUT® Surgical Guidance System (SAVI SCOUT). The SAVI SCOUT is a medical device, used to provide real-time guidance during localized excisional biopsy or…
- Trial name
- NCT02370082
- Testing
- Localization of breast lesion
- Volunteers
- 150 people
- Sponsor
- Cianna Medical, Inc.
Breast Tumors, Wound Healing
HealiAid Collagen Wound Dressing in Patients Undergoing Breast Tumor Surgery
The goal of this clinical trial is to evaluate the safety of the collagen wound dressing (HealiAid) in breast tumor patients with surgical treatment. The main questions it aims to answer are: 1.
- Conditions
- Breast Tumors, Wound Healing, Collagen Wound Dressing
- Trial name
- NCT07209020
- Testing
- HealiAid Collagen Wound Dressing
- Where
- 3 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- Maxigen Biotech Inc.
Breast Cancer
Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology
This study will evaluate LumaScan, an innovative polarization microscope for real time, intraoperative imaging and evaluation of the surface of excised tissue excised during Breast Conservation Surgery (BCS) for non invasive and…
- Trial name
- NCT02207179
- Testing
- LumaScan Image Guided Surgery
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- LumaMed
Radiation-induced Dermatitis
Study of ST266 Versus Saline in Treating Skin Irritation From Radiation
The objective of this study is to evaluate the safety and efficacy of ST266 in treating radiation burns of the skin in patients undergoing treatments for breast cancer and to compare ST266 treated burns with those treated with…
- Trial name
- NCT01714973
- Testing
- ST266
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Breast Fibroadenoma
MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas
The primary objective of this pivotal study is to evaluate the safety and efficacy of FUS treatment of breast fibroadenomas. Our hypothesis is that FUS lesion ablation of a fibroadenoma will have the following results: a.
- Trial name
- NCT00147108
- Testing
- ExAblate 2000
- Where
- 5 sites in United States, Japan
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- InSightec
Breast Cancer
Exploratory Study Comparing ClearSight System 2D Map to Post Surgery Histopathological Analysis in Lumpectomy
Prospective, single-arm, multicenter, open label, non-randomized exploratory clinical study comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
- Trial name
- NCT02679378
- Testing
- ClearSight™ System
- Where
- 5 sites in United States, Israel
- Volunteers
- 220 people
- Sponsor
- Clear Cut Medical Ltd.
Hypersensitivity Reactions
Post-market Safety Study of LUMISIGHT
This study is a prospective, multi-center, observational post-market safety study evaluating the incidence of anaphylaxis and hypersensitivity reactions associated with LUMISIGHT (pegulicianine) administration in adults with…
- Trial name
- NCT07572162
- Where
- 2 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Lumicell, Inc.
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast
Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
Phase 2, open-label study of AVB-620 in women with primary, nonrecurrent and nonmetastatic breast cancer undergoing surgery.
- Conditions
- Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast
- Trial name
- NCT03113825
- Testing
- Investigational Imaging device, AVB-620
- Where
- 13 sites in United States
- Volunteers
- 92 people
- Sponsor
- Avelas Biosciences, Inc.
Breast Cancer
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
This study will compare DS 8201a to standard treatment. Participants must have HER2 breast cancer that has been treated before. Their cancer: cannot be removed by an operation has spread to other parts of the body
- Trial name
- NCT03523585
- Testing
- Trastuzumab deruxtecan, Capecitabine, Lapatinib
- Where
- 227 sites in United States, Australia and 13 more
- Volunteers
- 608 people
- Sponsor
- Daiichi Sankyo
Secondary Lymphedema
Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)
This study evaluates the efficacy of Lymfactin® in patients with secondary lymphedema associated with the treatment of breast cancer by comparing the effects of active study treatment Lymfactin® to placebo.
- Trial name
- AdeLE (NCT03658967)
- Testing
- Lymfactin® (1x10E11 vp)
- Where
- 5 sites in Finland, Sweden
- Volunteers
- 39 people
- Sponsor
- Herantis Pharma Plc.
Breast Cancer
LightPathTM Imaging System for Ex-vivo Assessment of Margin and Lymph Node Status in Breast Cancer Surgical Specimens
This study is a prospective, cross-sectional observational single centre study to assess the feasibility of intra-operative Cerenkov Luminescence Imaging (CLI) of breast cancer wide local excision (WLE) specimens and dissected…
- Trial name
- NCT02037269
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Lightpoint Medical Limited
Radiodermatitis
Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients
This study, a nonrandomized open-label Phase I safety and exploratory study, will evaluate the safety of topical norepinephrine in post-surgical breast cancer patients who are undergoing radiation therapy.
- Trial name
- NCT01263366
- Testing
- Norepinephrine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- ProCertus BioPharm, Inc
Breast Cancer
Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer
This is a pilot "window of opportunity" clinical study in patients with operable breast cancer investigating use of reparixin as single agent in the time period between clinical diagnosis and surgery.
- Trial name
- NCT01861054
- Testing
- Reparixin
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dompé Farmaceutici S.p.A
Radiodermatitis
Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy
This study, a nonrandomized open-label safety and exploratory study, will evaluate the safety of topical norepinephrine in post-surgical breast cancer patients who are undergoing radiation therapy.
- Trial name
- NCT01544504
- Testing
- Norepinephrine
- Where
- United States
- Sponsor
- ProCertus BioPharm, Inc
Breast Cancer
A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer
This is a Phase II, randomised, double-blind, placebo-controlled study. Subjects with histologically-confirmed oestrogen receptor negative (ER-), progesterone receptor negative (PgR-) primary breast cancer breast cancer will be…
- Trial name
- NCT00252811
- Testing
- Gefitinib
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Sentinel Lymph Node Biopsy, Breast Cancer
A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery
This study was for women with breast cancer and for adults with melanoma. Breast cancer was a type of cancer when cells in the breast turn into cancer cells, which might grow out of control.
- Conditions
- Sentinel Lymph Node Biopsy, Breast Cancer, Melanoma
- Trial name
- NCT05457842
- Testing
- pudexacianinium chloride
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Astellas Pharma Inc
Breast Cancer
Breast Surgery Recovery: The Clinical and Psychosocial Impact of THEYA Recovery Range
A randomised interventional comparative control study will be undertaken to compare the THEYA Recovery Range postoperatively for patients undergoing wider lumpectomies, partial mastectomies and total mastectomies to current…
- Trial name
- NCT02593890
- Testing
- THEYA Recovery Range
- Volunteers
- 100 people
- Sponsor
- Claire Kelly
Triple Negative Breast Cancer
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC)…
- Trial name
- NCT05633654
- Testing
- Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine
- Where
- 376 sites in United States, Australia and 10 more
- Volunteers
- 1,514 people
- Sponsor
- Gilead Sciences
Breast Cancer
Improving Surgical/Medical Oncology Collaboration for Breast Cancer Treatment Planning: Pilot Testing the Impact of Continuing Education and Patient Care Planning
This study will explore provider's screening and management practices for eligibility for neoadjuvant therapy from baseline to following the project intervention (use of a novel existing technology, the Carevive Care Planning…
- Trial name
- NCT03161600
- Testing
- Carevive CPS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Carevive Systems, Inc.
Breast Cancer
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with…
- Trial name
- NCT05629585
- Testing
- Dato-DXd, Durvalumab, Capecitabine
- Where
- 276 sites in United States, Belgium and 15 more
- Volunteers
- 1,174 people
- Sponsor
- AstraZeneca